LP-65
General Information
DRACP ID DRACP00832
Peptide Name LP-65
Sequence IEELLKKAEEQQKKNEEELKKLEX
Sequence Length 24
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP Induce apoptosis
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
TZM-bl | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | 50% Cytotoxicity=256.23±14.58µM | CellTiter 96 AQueous One Solution assay | 48h | 1 |
MT-4 | Human acute lymphoblastic leukemia cell line | Leukemia | 50% Cytotoxicity=213.4±59.59µM | CellTiter 96 AQueous One Solution assay | 48h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HEK293T: 50% Cytotoxicity=208.43±22.9 µM; PBMC: 50% Cytotoxicity=49.95±2.97 µM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antiviral
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Acetylation
C-terminal Modification Amidation
Other Modification X(24)= Lysine with palmitoylated side group
Chiral L
Physicochemical Information
Formula C123H210N32O42
Absent amino acids CDFGHMPRSTVWY
Common amino acids E
Mass 332964
Pl 4.6
Basic residues 6
Acidic residues 8
Hydrophobic residues 6
Net charge -2
Boman Index -7909
Hydrophobicity -168.33
Aliphatic Index 85.42
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 1
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 30089693
Title Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
Year 2018
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available